The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
Abstract
We recently reported that mice deficient in the programmed cell death-1 (PD-1) immunoinhibitory coreceptor develop autoimmune dilated cardiomyopathy (DCM), with production of high-titer autoantibodies against a heart-specific, 30-kDa protein. In this study, we purified the 30-kDa protein from heart extract and identified it as cardiac troponin I (cTnI), encoded by a gene in which mutations can cause familial hypertrophic cardiomyopathy (HCM). Administration of monoclonal antibodies to cTnI induced dilatation and dysfunction of hearts in wild-type mice. Monoclonal antibodies to cTnI stained the surface of cardiomyocytes and augmented the voltage-dependent L-type Ca2+ current of normal cardiomyocytes. These findings suggest that antibodies to cTnI induce heart dysfunction and dilatation by chronic stimulation of Ca2+ influx in cardiomyocytes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the cardiotoxicity of anti-cTnI autoantibodies has been reported in studies using BALB/c mice lacking PD-1 expression”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
In the citing paper
“PD-1-deficient BALB/c mice spontaneously developed autoimmune DCM mediated by anti-cTnI antibodies, and the pathology was transferable when wild-type mice were treated with these autoantibodies”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
In the citing paper
“suggesting a potential mechanism of ICI myocarditis.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
In the citing paper
“the cardiotoxicity of anti-cTnI antibodies has been reported in PD-1 -/- BALB/c mice”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
In the citing paper
“However, these autoantibodies are generally not disease-specific and may not consistently induce the disease phenotype in murine models, indicating their limitations as diagnostic and therapeutic targets. 57,92,97,191”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
Citations
Cites
Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00656997 · Cited by 18,436
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Self-citationThe Genetic Basis for Cardiomyopathy
Seidman, J. G., & Seidman, C. (2001) · Cell · doi:10.1016/s0092-8674(01)00242-2 · Cited by 1,046
Calcium tolerant ventricular myocytes prepared by preincubation in a ?KB medium?
Isenberg, G., & Klockner, U. (1982) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/bf00584963 · Cited by 898
Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy
Kamisago, M., Sharma, S. D., DePalma, S. R., Solomon, S., Sharma, P., McDonough, B., Smoot, L., Mullen, M. P., Woolf, P. K., Wigle, E. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432304 · Cited by 720
Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy
Kimura, A., Harada, H., Park, J.-E., Nishi, H., Satoh, M., Takahashi, M., Hiroi, S., Sasaoka, T., Ohbuchi, N., Nakamura, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0897-379 · Cited by 577
Cardiac myosin induces myocarditis in genetically predisposed mice.
Neu, N., Rose, N. R., Beisel, K. W., Herskowitz, A., Gurri-Glass, G., & Craig, S. W. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.11.3630 · Cited by 526
Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12
Shou, W., Aghdasi, B., Armstrong, D. L., Guo, Q., Bao, S., Charng, M.-J., Mathews, L. M., Schneider, M. D., Hamilton, S. L., & Matzuk, M. M. (1998) · Nature · doi:10.1038/35146 · Cited by 431
Cited by
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Caforio, A. L. P., Pankuweit, S., Arbustini, E., Basso, C., Gimeno-Blanes, J., Felix, S. B., Fu, M., Heliö, T., Heymans, S., Jahns, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht210 · Cited by 3,479
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Self-citationCo-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease
Del Re, D. P., Amgalan, D., Linkermann, A., Liu, Q., & Kitsis, R. N. (2019) · Physiological Reviews · doi:10.1152/physrev.00022.2018 · Cited by 961
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Self-citationCardioimmunology: the immune system in cardiac homeostasis and disease
Swirski, F. K., & Nahrendorf, M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0065-8 · Cited by 849
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
The PD-1–PD-L pathway in immunological tolerance
Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 721
Self-citationSchultheiss, H.-P., Fairweather, D., Caforio, A. L. P., Escher, F., Hershberger, R. E., Lipshultz, S. E., Liu, P. P., Matsumori, A., Mazzanti, A., McMurray, J., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0084-1 · Cited by 720
Self-citationOsorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 635
Self-citationThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
Immune checkpoint inhibitors and cardiovascular toxicity
Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 531
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Application of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 531
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Blank, C., & Mackensen, A. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0272-1 · Cited by 505
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511
Cardiovascular toxicities associated with immune checkpoint inhibitors
Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz026 · Cited by 508
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., & Honjo, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505497102 · Cited by 437
Self-citationTroponin Elevation in Heart Failure
Kociol, R. D., Pang, P. S., Gheorghiade, M., Fonarow, G. C., O'Connor, C. M., & Felker, G. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.016 · Cited by 443
Chamoto, K., Chowdhury, P. S., Kumar, A., Sonomura, K., Matsuda, F., Fagarasan, S., & Honjo, T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620433114 · Cited by 413
Self-citationDennert, R., Crijns, H. J., & Heymans, S. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn296 · Cited by 411
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy
Heymans, S., Eriksson, U., Lehtonen, J., & Cooper, L. T. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.937 · Cited by 359
Toi, Y., Sugawara, S., Sugisaka, J., Ono, H., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5860 · Cited by 352
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Okazaki, T., Okazaki, I.-M., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato, Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100466 · Cited by 324
Self-citationHeymans, S., Hirsch, E., Anker, S. D., Aukrust, P., Balligand, J.-L., Cohen-Tervaert, J. W., Drexler, H., Filippatos, G., Felix, S. B., Gullestad, L., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn043 · Cited by 323
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
Role of PD-1 in Regulating T-Cell Immunity
Jin, H.-T., Ahmed, R., & Okazaki, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_116 · Cited by 305
Self-citationWeber, J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.005 · Cited by 306
Wang, S., Li, W., Zhang, P., Wang, Z., Ma, X., Liu, C., Vasilev, K., Zhang, L., Zhou, X., Liu, L., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.01.004 · Cited by 295
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 299
Toi, Y., Sugawara, S., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Tsurumi, K., Suzuki, K., Shimizu, H., Sugisaka, J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0384 · Cited by 294
Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8 + T-Cell–Mediated Injury in the Heart
Grabie, N., Gotsman, I., DaCosta, R., Pang, H., Stavrakis, G., Butte, M. J., Keir, M. E., Freeman, G. J., Sharpe, A. H., & Lichtman, A. H. (2007) · Circulation · doi:10.1161/circulationaha.107.709360 · Cited by 288
Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0856 · Cited by 290
Self-citationPD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Gianchecchi, E., Delfino, D. V., & Fierabracci, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.003 · Cited by 270
PD-1/PD-L and autoimmunity: A growing relationship
Zamani, M. R., Aslani, S., Salmaninejad, A., Javan, M. R., & Rezaei, N. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.09.009 · Cited by 266
Mumprecht, S., Schürch, C., Schwaller, J., Solenthaler, M., & Ochsenbein, A. F. (2009) · Blood · doi:10.1182/blood-2008-09-179697 · Cited by 267
Advances in targeting cell surface signalling molecules for immune modulation
Yao, S., Zhu, Y., & Chen, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3877 · Cited by 267
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Wang, J., Okazaki, I.-M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 270
Self-citationCardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
“IgG antibodies against cardiac troponin I were found in the circulation with IgG deposits on the surface of cardiomyocytes, where they were thought to enhance L-type Ca2+ channel currents (141).”
BackgroundCell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 229
Cardiovascular Toxicities of Immune Checkpoint Inhibitors
Ball, S., Ghosh, R. K., Wongsaengsak, S., Bandyopadhyay, D., Ghosh, G. C., Aronow, W. S., Fonarow, G. C., Lenihan, D. J., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.079 · Cited by 222
Göser, S., Andrassy, M., Buss, S. J., Leuschner, F., Volz, C. H., Öttl;, R., Zittrich;, S., Blaudeck, N., Hardt, S. E., Pfitzer, G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.635664 · Cited by 224
The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity
Khoury, S. J., & Sayegh, M. H. (2004) · Immunity · doi:10.1016/s1074-7613(04)00116-5 · Cited by 209
Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease
Totzeck, M., Schuler, M., Stuschke, M., Heusch, G., & Rassaf, T. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.01.038 · Cited by 206
PD-1/PD-L1 Pathway in Breast Cancer
Schütz, F., Stefanovic, S., Mayer, L., von Au, A., Domschke, C., & Sohn, C. (2017) · Oncology Research and Treatment · doi:10.1159/000464353 · Cited by 196
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
Parekh, V. V., Lalani, S., Kim, S., Halder, R., Azuma, M., Yagita, H., Kumar, V., Wu, L., & Van Kaer, L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803648 · Cited by 197
Smoldering myocarditis following immune checkpoint blockade
Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L., McKee, S. B., Gertler, A. S., Moslehi, J. J., & Conry, R. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0296-4 · Cited by 201
Chowdhury, P. S., Chamoto, K., & Honjo, T. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 191
Self-citationLucas, J. A., Menke, J., Rabacal, W. A., Schoen, F. J., Sharpe, A. H., & Kelley, V. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2513 · Cited by 189
Li, B., VanRoey, M., Wang, C., Chen, T.-H. T., Korman, A., & Jooss, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1825 · Cited by 191
Autoantibodies in Heart Failure and Cardiac Dysfunction
Kaya, Z., Leib, C., & Katus, H. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.243360 · Cited by 187
Frantz, S., Falcao-Pires, I., Balligand, J.-L., Bauersachs, J., Brutsaert, D., Ciccarelli, M., Dawson, D., de Windt, L. J., Giacca, M., Hamdani, N., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1138 · Cited by 184
Zhong, X., Tumang, J. R., Gao, W., Bai, C., & Rothstein, T. L. (2007) · European Journal of Immunology · doi:10.1002/eji.200737461 · Cited by 190
Oscillating CD8+ T Cell Effector Functions after Antigen Recognition in the Liver
Isogawa, M., Furuichi, Y., & Chisari, F. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.005 · Cited by 186
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
Self-citationBajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., et al. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3750 · Cited by 179
“Another study published in Nature Medicine reported that mice deficient in the PD-1 immuno-inhibitory co-receptor develop autoimmune dilated cardiomyopathy with production of high titer autoantibodies against a heart specific protein [115].”
BackgroundCardiac Troponins in Dogs and Cats
Langhorn, R., & Willesen, J. L. (2016) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.13801 · Cited by 161
Yoest, J. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s126227 · Cited by 176
Caforio, A. L. P., Mahon, N. G., Baig, M. K., Tona, F., Murphy, R. T., Elliott, P. M., & McKenna, W. J. (2007) · Circulation · doi:10.1161/circulationaha.106.641472 · Cited by 174
Molecular genetics and genomics of heart failure
Liew, C.-C., & Dzau, V. J. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1470 · Cited by 171
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy
Michel, L., Helfrich, I., Hendgen-Cotta, U. B., Mincu, R.-I., Korste, S., Mrotzek, S. M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab430 · Cited by 168
Expression and function of PD‐1 in human γδ T cells that recognize phosphoantigens
Iwasaki, M., Tanaka, Y., Kobayashi, H., Murata‐Hirai, K., Miyabe, H., Sugie, T., Toi, M., & Minato, N. (2011) · European Journal of Immunology · doi:10.1002/eji.201040959 · Cited by 158
Self-citationCaforio, A. L. P., Brucato, A., Doria, A., Brambilla, G., Angelini, A., Ghirardello, A., Bottaro, S., Tona, F., Betterle, C., Daliento, L., et al. (2010) · Heart · doi:10.1136/hrt.2009.187138 · Cited by 169
Lehmann, L. H., Heckmann, M. B., Bailly, G., Finke, D., Procureur, A., Power, J. R., Stein, F., Bretagne, M., Ederhy, S., Fenioux, C., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.062405 · Cited by 165
Ono, M., Shimizu, J., Miyachi, Y., & Sakaguchi, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4748 · Cited by 162
Myocarditis in Humans and in Experimental Animal Models
Błyszczuk, P. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00064 · Cited by 161
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 162
Cardiotoxicity of Immune Checkpoint Inhibitors
Patel, R. P., Parikh, R. B., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01070-6 · Cited by 162
Pathophysiology and biochemistry of cardiovascular disease
Scott, J. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.04.012 · Cited by 153
Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy
Caforio, A. L. P., Tona, F., Bottaro, S., Vinci, A., Dequal, G., Daliento, L., Thiene, G., & Iliceto, S. (2008) · Autoimmunity · doi:10.1080/08916930701619235 · Cited by 157
A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese
Kong, E. K., Prokunina‐Olsson, L., Wong, W. H. S., Lau, C., Chan, T. M., Alarcón-Riquelme, M. E., & Lau, Y. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20966 · Cited by 155
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. L., & Neilan, T. G. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 162
Martín‐Orozco, N., Wang, Y.-H., Yagita∥, H., & Dong, C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8291 · Cited by 156
Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137
Prognostic and predictive markers for the new immunotherapies.
Mahoney, K. M., & Atkins, M. B. (2014) · PubMed · Cited by 138
Möhn, N., Beutel, G., Gutzmer, R., Ivanyi, P., Satzger, I., & Skripuletz, T. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111777 · Cited by 141
Störk, S., Boivin, V., Horf, R., Hein, L., Lohse, M. J., Angermann, C. E., & Jahns, R. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.004 · Cited by 135
“These include membrane proteins,(5,6,11,12,28) mitochondrial proteins,(29,30) and/or myocyte structural proteins.(25,31) Genetic factors may”
Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
Xiao, G., Deng, A., Liu, H., Ge, G., & Liu, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206370109 · Cited by 133
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 144
Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 143
Tocchetti, C. G., Dessalvi, C. C., Lisi, D. D., Femminò, S., Madonna, R., Mele, D., Monte, I. P., Novo, G., Penna, C. R. R., Pepe, A., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6930 · Cited by 142
Orchestrating immune check-point blockade for cancer immunotherapy in combinations
Perez‐Gracia, J. L., Labiano, S., Rodriguez-Ruiz, M. E., Sanmamed, M. F., & Melero, I. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.002 · Cited by 138
The role of B-1 cells in inflammation
Aziz, M., Holodick, N. E., Rothstein, T. L., & Wang, P. (2015) · Immunologic Research · doi:10.1007/s12026-015-8708-3 · Cited by 130
Cardiotoxicity from immune checkpoint inhibitors
Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 148
Kong, Y.-C. M., & Flynn, J. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00206 · Cited by 135
T cell checkpoint regulators in the heart
Grabie, N., Lichtman, A. H., & Padera, R. F. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz025 · Cited by 131
Mir, H. R., Alhussein, M. M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S. D., Nair, V., & Leong, D. P. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.012 · Cited by 127
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Flies, D. B., Sandler, B. J., Sznol, M., & Chen, L. (2011) · PubMed Central · Cited by 143
Metadata
- Authors
- Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- Mie University (JP)
- Corresponding author
- Honjo, Tasuku
- ORCID
- Venue
- Nature Medicine
- Published
- 2003-11-02
- Volume
- 9
- Issue
- 12
- Pages
- 1477-1483
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2140419562
- Semantic Scholar
- 8b8bf12ad1a303d244e325c58410b356c4ed2945
- Cited by
- 689
- References
- 38
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 44 · 2023: 36 · 2022: 49 · 2021: 49 · 2020: 47 · 2019: 46 · 2018: 28 · 2017: 30 · 2016: 32 · 2015: 19 · 2014: 20 · 2013: 22 · 2012: 16
- FWCI
- 16.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- cardiac troponin I, autoantibodies, dilated cardiomyopathy, PD-1 deficiency, autoimmune cardiomyopathy, familial hypertrophic cardiomyopathy, L-type calcium current, cardiac dysfunction, monoclonal antibodies
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Surface, Autoantibodies, Base Sequence, Cardiomyopathy, Dilated, Humans, Mice, Inbred A, Mice, Inbred BALB C, Mice, Nude, Antigens, CD, Rats, Wistar, DNA, Complementary, Mice, Knockout, Troponin I, Calcium Signaling, Myocytes, Cardiac, Apoptosis Regulatory Proteins, Mice, Rats, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.